Status:
UNKNOWN
Determinants of Warfarin Metabolism
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Healthy
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolis...
Eligibility Criteria
Inclusion
- Age range of 20-50 years old
- The absence of significant disease states
Exclusion
- Known hypersensitivity to warfarin or phenytoin
- The presence of significant disease states
- Regular use of drugs (including birth control pills)
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00162474
Start Date
September 1 2003
End Date
December 1 2020
Last Update
June 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel